和鉑醫藥將在抗體工程和治療大會發布最新自研雙特異抗體
格隆匯6月8日丨2021 Antibody Engineering & Therapeutics(AET)大會於6月8日至10日在線召開,和鉑醫藥將於大會上以學術海報形式發佈基於自有抗體技術平台HBICETM(基於HCAb的免疫細胞銜接器平台)研發的雙特異性抗體HBM7022。
和鉑醫藥(2142.HK)是一家專注於腫瘤及免疫性疾病領域創新藥研發及商業化的全球化生物製藥企業。公司通過自主研發、聯合開發及多元化的合作模式快速拓展創新藥研發管線。

雙特異性抗體HBM7022是和鉑自研的全新腫瘤免疫治療藥物,和鉑將於大會上展示其獨特的作用機制和強大的抗腫瘤效果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.